Yukio NAKAMURA, et al. “Tofacitinib Versus Non-Tumor Necrosis Factor Biologics for Patients With Active Rheumatoid Arthritis”. Archives of Rheumatology, vol. 33, no. 2, June 2018, pp. 154-9, doi:10.5606/ArchRheumatol.2018.6366.